NCT02800486: Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- State
- Under way
- Phase
- Phase 2
- People
- 37 planned
- Started
- May 2016
- Primary completion
- May 2035
- Arms
- Intra-arterial Cetuximab with Re-Irradiation
- Results
- None posted
- 15 Jun 2016: Trial registered